Skip to main content

Table 1 Characteristics of children with JIA starting treatment with etanercept (N = 197) at baseline

From: Predictors of the response to etanercept in patients with juvenile idiopathic arthritis without systemic manifestations within 12 months: results of an open-label, prospective study conducted at the National Scientific and Practical Center of Children's Health, Russia

Characteristics All patients (n = 197) Persistent oligoarticular Extended oligoarticular Polyarticular RF negative Enthesitis-related
(n = 84) (n = 23) (n = 64) (n = 24)
Female, n (%) 137 (69.5) 68 (81.0) 16 (69.6) 46 (71.9) 5(20.8)d
Age at JIA onset, median (IQR), years 3 (2 – 7) 2.3 (1.7 – 3.7)a 2 (1.5 – 4) 3.25 (2 – 7.5)a 9 (5 – 11.8)d
Age at start of etanercept, median (IQR), years 7.25 (4 – 12) 5.1 (2.9 – 8.9)a 7.5 (3.5 – 10) 9 (5.8 – 13)a 13 (10.9 – 15.0)d
Disease duration before start etanercept, median (IQR), years 2.1 (1 – 5) 1.9 (0.9 – 4)a 3 (1.7 – 7) 3.5 (1.8 – 6)a 3 (1.5 – 5)
History of chronic anterior uveitis, n (%) 7 (3.6) 3 (3.6) 1 (4.3) 3 (4.7) 0 (0)
History of at least 1 DMARD use except MTX, n (%) 84 (42.6) 24 (28.6)ab 7 (30.4)c 34 (53.1)a 18 (75.0)bc
History of at least 1 DMARD use, n (%) 170 (86.3) 69 (82.1) 22 (95.7) 57 (89.1) 22 (91.7)
History of ≥2 DMARDs use, n (%) 76 (38.6) 21 (25.0)ab 6 (26.1) 32 (50.0)a 15 (62.5)b
History of at least 1 biologic use, n (%) 44 (22.3) 10 (11.9)a 5 (21.7) 20 (31.3)a 7 (29.2)
History of ≥2 biologics use, n (%) 7 (3.6) 1 (1.2) 0 (0) 5 (7.8) 1 (4.2)
History of oral steroid use, n (%) 55 (27.9) 8 (9.5)ab 7 (30.4) 30 (46.9)a 8 (33.3)b
Concurrent MTX use, n (%) 136 (69.0) 51 (60.7)a 21 (91.3)ab 51 (79.7) 12 (50.0)b
Concurrent sulfasalazin use, n (%) 6 (3.0) 1 (1.2) 0 (0) 2 (3.1) 3 (12.5)
Concurrent oral steroid use, n (%) 10 (5.1) 0 (0) 2 (8.7) 5 (7.8) 3 (12.5)
NSAID use, n (%) 121 (61.4) 44 (52.4) 15 (65.2) 43 (67.2) 18 (75.0)
  1. Paired superscript letters (a, b, c) denote the existence of differences between two groups in each line (p < 0.05). The superscript letter d denotes the difference between indicators in one group and those in all other groups. RF rheumatoid factor, IQR interquartile range, DMARD disease-modifying antirheumatic drugs, MTX Methotrexate, NSAID nonsteroidal anti-inflammatory drugs